TB-500 peptide guide

The full-length thymosin beta-4 protein helps cells move and helps wounds close. It does this by binding to a building block called G-actin and controlling how much of it can join into the long fibers (F-actin) that give cells their structure and ability to migrate.

Inside the longer Tβ4 protein, the central LKKTETQ region — the same sequence that makes up TB-500 — has been described in published research as the part most directly linked to wound healing, cell migration, and new blood vessel formation (angiogenesis). That observation is the reason researchers study TB-500 as a stand-alone peptide rather than the full protein.

Important boundary: most of the published mechanism work uses the full 43-amino-acid Tβ4 protein, not the 7-amino-acid TB-500 fragment. Whether the fragment reproduces every effect of the full protein at typical research doses is not fully settled. I checked the original mechanism papers in Nature (2004) and EMBO Journal (2004) directly to confirm this distinction.

The strongest human evidence in this space comes from a Phase 3 randomized, placebo-controlled, double-masked trial of 0.1% RGN-259 (a topical thymosin beta-4 eye drop) in patients with neurotrophic keratopathy, published in 2023 in PMC. RGN-259-treated patients showed faster corneal healing and improved comfort versus placebo. Earlier Phase 2 work in severe dry eye disease (NCT01393132, Cornea 2015) reported a 35.1% reduction in ocular discomfort and a 59.1% reduction in corneal staining at day 56 versus vehicle, in a small 9-patient trial. Both used full-length Tβ4 in a topical eye-drop formulation, not injected TB-500.

For chronic skin wounds, Phase 2 trials of topical Tβ4 gel in pressure ulcers (NCT00382174) and venous stasis ulcers reported faster healing — by approximately one month in patients who healed — across 143 patients in one program. These trials used full-length Tβ4 applied topically to the wound surface. They did not test injected TB-500.

For musculoskeletal repair, cardiac repair, and the broader claims most often associated with TB-500, the evidence is preclinical. A 2004 Nature paper (Bock-Marquette et al.) showed full-length Tβ4 promotes cardiac cell migration and survival in mouse models. Multiple papers since have shown wound healing, tendon repair, and angiogenesis effects in rodent and equine studies. As of April 2026, no published randomized controlled trial in humans has tested the injected TB-500 7-amino-acid fragment for any musculoskeletal, cardiac, or systemic indication. This is a real evidence gap that supplier marketing does not always make clear.

Observed safety data in humans is limited and almost all comes from topical Tβ4 trials, not injected TB-500. In Phase 2 ulcer and dry-eye trials, topical Tβ4 was reported as safe and well-tolerated, with no significant adverse effects in published results. There is no comparable published safety dataset for the injected TB-500 7-amino-acid fragment.

Theoretical risks discussed in the literature focus on angiogenesis. Full-length Tβ4 promotes new blood vessel growth in animal models, and Tβ4 has been observed to be upregulated in some tumor microenvironments (Cha et al., J Natl Cancer Inst 2003). No direct cancer-promoting effect of exogenous TB-500 has been demonstrated in healthy animal models, but the angiogenic mechanism is why most clinical discussions exclude patients with active or recent cancer.

As of April 2026, TB-500 is not approved by the FDA for any indication. The FDA placed TB-500 in 503A Category 2 in 2023 (significant safety concerns for compounding), then announced on April 15, 2026 that 12 peptides — including TB-500 — would be removed from Category 2 effective seven days later because the original nominations were withdrawn. The FDA confirmed in the same notice that TB-500 (free base and acetate forms) will be reviewed by the Pharmacy Compounding Advisory Committee on July 23, 2026 for possible inclusion on the 503A Bulks List. Removal from Category 2 is procedural and does not authorize compounding on its own. The World Anti-Doping Agency lists "Thymosin-β4 and its derivatives e.g. TB-500" under section S2.3 (Growth Factors) of the 2026 Prohibited List, prohibited at all times for athletes under WADA jurisdiction.